BR112018013227A2 - ?composições farmacêuticas ou kit para o uso, métodos para tratar câncer em um mamífero e uso de uma composição? - Google Patents

?composições farmacêuticas ou kit para o uso, métodos para tratar câncer em um mamífero e uso de uma composição?

Info

Publication number
BR112018013227A2
BR112018013227A2 BR112018013227A BR112018013227A BR112018013227A2 BR 112018013227 A2 BR112018013227 A2 BR 112018013227A2 BR 112018013227 A BR112018013227 A BR 112018013227A BR 112018013227 A BR112018013227 A BR 112018013227A BR 112018013227 A2 BR112018013227 A2 BR 112018013227A2
Authority
BR
Brazil
Prior art keywords
mammal
kit
composition
methods
pharmaceutical compositions
Prior art date
Application number
BR112018013227A
Other languages
English (en)
Inventor
GAY Fabien
Aguera Karine
BERLIER Willy
Godfrinn Yann
Original Assignee
Erytech Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erytech Pharma filed Critical Erytech Pharma
Publication of BR112018013227A2 publication Critical patent/BR112018013227A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01001—Asparaginase (3.5.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y404/00—Carbon-sulfur lyases (4.4)
    • C12Y404/01—Carbon-sulfur lyases (4.4.1)
    • C12Y404/01011—Methionine gamma-lyase (4.4.1.11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Botany (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

a invenção está relacionada com um novo método para o tratamento de cânceres líquidos e sólidos em um mamífero, incluindo humanos, em que a metioninase é administrada antes da asparaginase. a invenção também abrange o uso de uma privação de metionina na dieta, possivelmente combinada com a administração de metioninase, antes do tratamento com asparaginase. a metioninase e a asparaginase podem ser utilizadas, em particular sob forma livre, forma peguilada ou encapsulada em eritrócitos.
BR112018013227A 2015-12-31 2017-01-02 ?composições farmacêuticas ou kit para o uso, métodos para tratar câncer em um mamífero e uso de uma composição? BR112018013227A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15307197.2A EP3187190A1 (en) 2015-12-31 2015-12-31 Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
PCT/EP2017/050006 WO2017114966A1 (en) 2015-12-31 2017-01-02 Method of treating a mammal, including human, against cancer using methionine and asparagine depletion

Publications (1)

Publication Number Publication Date
BR112018013227A2 true BR112018013227A2 (pt) 2018-12-04

Family

ID=55079994

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018013227A BR112018013227A2 (pt) 2015-12-31 2017-01-02 ?composições farmacêuticas ou kit para o uso, métodos para tratar câncer em um mamífero e uso de uma composição?

Country Status (16)

Country Link
US (2) US11141468B2 (pt)
EP (2) EP3187190A1 (pt)
JP (1) JP6966451B2 (pt)
KR (1) KR102268259B1 (pt)
CN (1) CN108472339B (pt)
AU (1) AU2017204678B2 (pt)
BR (1) BR112018013227A2 (pt)
CA (1) CA3009918C (pt)
ES (1) ES2881787T3 (pt)
HK (1) HK1256155A1 (pt)
IL (1) IL260278B (pt)
JO (1) JO3709B1 (pt)
MX (1) MX2018007933A (pt)
RU (1) RU2733389C2 (pt)
SG (1) SG11201805311XA (pt)
WO (1) WO2017114966A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2930665A1 (en) 2013-11-18 2015-05-21 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
FR3017299B1 (fr) * 2014-02-12 2018-05-18 Erytech Pharma Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
US10869898B2 (en) 2014-04-01 2020-12-22 Rubius Therapeutics, Inc. Methods and compositions for immunomodulation
EP3187190A1 (en) * 2015-12-31 2017-07-05 Erytech Pharma Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
CA3010510A1 (en) 2016-01-11 2017-07-20 Rubius Therapeutics, Inc. Compositions and methods related to multimodal therapeutic cell systems for immune indications
JP7176921B2 (ja) 2017-10-19 2022-11-22 アンチキャンサー インコーポレーテッド 癌治療、予防及びアンチエイジングのための組み換えメチオニナーゼを含む製剤
WO2020043321A1 (en) 2018-08-31 2020-03-05 Stichting Katholieke Universiteit Synergistic combinations of amino acid depletion agent sensitizers (aadas) and amino acid depletion agents (aada), and therapeutic methods of use thereof
SG11202104205XA (en) * 2018-10-26 2021-05-28 Univ Texas Engineered primate cystine/cysteine degrading enzymes for therapeutic uses
EP3880309A1 (en) * 2018-11-15 2021-09-22 Erytech Pharma Synergistic combinations of methionine depletion agents and immune checkpoint modulators
US20230226218A1 (en) 2020-05-11 2023-07-20 Erytech Pharma Red Cell Extracellular Vesicles (RCEVs) Containing Cargoes and Methods of Use and Production Thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891704A (en) * 1992-11-19 1999-04-06 Anticancer, Inc. Method to produce high levels of methioninase
US5715835A (en) * 1992-11-19 1998-02-10 Anticancer, Inc. Methods for treating and reducing the potential for cardiovascular disease using methioninase compositions
US6017962A (en) * 1997-02-27 2000-01-25 Board Of Regents, The University Of Texas System Method of depletion of methionine in plasma and solid tumors and uses thereof
CA2284111C (en) 1997-03-13 2009-05-19 Shionogi And Co., Ltd. Process for production of l-methionine .gamma.-lyase crystals
CN101579362A (zh) * 1999-10-04 2009-11-18 维昂药品公司 用于将效应分子定向递送至肿瘤的组合物及方法
US7351729B2 (en) * 2002-03-08 2008-04-01 Signal Pharmaceuticals, Llc JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers
EP1531823A4 (en) * 2002-05-10 2007-07-18 Univ Ohio State FLAVIN N-OXIDE: NEW CANCER AND MEANS TO REMOVE ENTANGERS
US20050234009A1 (en) * 2004-03-29 2005-10-20 Johnson Candace S Method of treating solid tumors and leukemias using combination therapy of vitamin D and anti-metabolic nucleoside analogs
FR2873925B1 (fr) 2004-08-05 2006-10-13 Erytech Pharma Soc Par Actions Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes
US20100284982A1 (en) * 2007-12-20 2010-11-11 Yang Victor C Erythrocyte-encapsulated L-asparaginase for enhanced acute lymphoblastic leukemia therapy
AU2013237419B2 (en) 2012-03-21 2016-04-28 Erytech Pharma Medicament for the treatment of acute myeloid leukemia (AML)
CN108686203A (zh) * 2012-04-04 2018-10-23 哈洛齐梅公司 使用抗透明质酸剂和肿瘤靶向紫杉烷的组合疗法
FR3005420B1 (fr) 2013-05-07 2015-09-18 Erytech Pharma Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.
WO2015042204A1 (en) * 2013-09-17 2015-03-26 The Regents Of The University Of California Enzyme-encapsulated nanoparticle platform
FR3017299B1 (fr) 2014-02-12 2018-05-18 Erytech Pharma Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
EP3187190A1 (en) * 2015-12-31 2017-07-05 Erytech Pharma Method of treating a mammal, including human, against cancer using methionine and asparagine depletion

Also Published As

Publication number Publication date
JP6966451B2 (ja) 2021-11-17
ES2881787T3 (es) 2021-11-30
CA3009918A1 (en) 2017-07-06
EP3397272A1 (en) 2018-11-07
CA3009918C (en) 2024-01-02
JO3709B1 (ar) 2021-01-31
JP2019500386A (ja) 2019-01-10
IL260278B (en) 2022-03-01
SG11201805311XA (en) 2018-07-30
EP3187190A1 (en) 2017-07-05
AU2017204678A1 (en) 2018-07-12
AU2017204678B2 (en) 2021-12-09
RU2018123666A (ru) 2019-12-31
MX2018007933A (es) 2018-08-09
RU2018123666A3 (pt) 2020-02-26
WO2017114966A1 (en) 2017-07-06
KR20180097596A (ko) 2018-08-31
CN108472339B (zh) 2022-02-15
US20220040272A1 (en) 2022-02-10
KR102268259B1 (ko) 2021-06-24
US11141468B2 (en) 2021-10-12
CN108472339A (zh) 2018-08-31
IL260278A (en) 2018-07-31
HK1256155A1 (zh) 2019-09-13
EP3397272B1 (en) 2021-06-23
US20190000941A1 (en) 2019-01-03
RU2733389C2 (ru) 2020-10-01

Similar Documents

Publication Publication Date Title
BR112018013227A2 (pt) ?composições farmacêuticas ou kit para o uso, métodos para tratar câncer em um mamífero e uso de uma composição?
MX2021001439A (es) Composiciones y metodos para el tratamiento de la disfuncion de la glandula de meibomio.
BR112017018368A2 (pt) composições contendo rna para o tratamento de doenças tumorais
EA201792623A1 (ru) Композиции, содержащие ингибитор стволовости рака и иммунотерапевтический агент, для применения в лечении рака
BR112015026006A8 (pt) composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112018070852A2 (pt) composições de dissulfeto de selênio para uso no tratamento de disfunção das glândulas meibomianas
BR112016006978A2 (pt) inibidores de tirosina quinase de bruton
BR112015027288A8 (pt) uso de uma dose de imunossupressor, composição de nanocarreadores sintéticos tolerogênicos e kit
BR112015022047A8 (pt) uso de uma composição compreendendo nanopartículas contendo um fármaco da família limo e uma albumina
BR112015019064A8 (pt) uso de uma composição compreendendo nanopartículas compreendendo paclitaxel e uma albumina para o tratamento de melanoma e kit
BR112015015870A8 (pt) composição farmacêutica, e, uso de uma composição farmacêutica
CL2019002190A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)
BR112019006463A2 (pt) composição oral de canabinoides extraídos e métodos de uso da mesma
BR112015019264A8 (pt) cápsulas para o tratamento de helicobacter pylori e seu uso".
BR112015025424A2 (pt) tratamento de câncer usando terapias de combinação de coenzima q10
EA201690159A1 (ru) Способы и композиции для лечения рака
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
CO2020010193A2 (es) Una composición farmacéutica para la anemia
AR102780A1 (es) Composiciones farmacéuticas, su preparación y sus usos
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
BR112018076639A2 (pt) quimioterapias de combinação
BR112014030534A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de doenças associadas com óxido nítrico sintase induzível elevada
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
BR112017007748A2 (pt) “composição farmacêutica, agente antialérgico, composição alimentar, composição cosmética, uso de um extrato, e, método para prevenir ou tratar uma doença alérgica
BR112014030279A2 (pt) métodos para tratamento de neutropenia usando agonistas retinóide

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements